GRACE – Glucose Reduction and Atherosclerosis Continuing Evaluation Study
Eva Lonn - McMaster University, Hamilton, Ontario, Canada
Hertzel C. Gerstein - McMaster University, Hamilton, Ontario, Canada
The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (GRACE) is a multicentre clinical trial with a 2×2 factorial design and a substudy of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. The principal aim of the trial was to investigate the effect of Omega 3 Fatty Acid (1g/day) or Insulin Glargine (target fasting glucose ≤5.3mg/dL) on cardiovascular morbidity and mortality in people at high risk for vascular disease. Individuals were eligible for inclusion if they were aged 50 years and older, had either impaired fasting glucose and/or impaired glucose tolerance or early diabetes, and had at least one cardiovascular risk factor. The study was approved by the ethics review boards of all participating institutions, and all participants provided written informed consent.
Link to study webpage – https://clinicaltrials.gov/ct2/show/NCT00069784
Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events: The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE). Diabetes Care. 2013 Sep;36(9):2466-74